Medical treatment of ectopic pregnancy: case report

Authors

  • Zaineb Chatbi Department of Gynecology and Obstetrics, Mohammed VI University Hospital, Oujda, Morocco
  • Soukaina Fekkoul Department of Gynecology and Obstetrics, Mohammed VI University Hospital, Oujda, Morocco
  • Inas Rhazi Department of Gynecology and Obstetrics, Mohammed VI University Hospital, Oujda, Morocco
  • Hafsa Tahiri Department of Gynecology and Obstetrics, Mohammed VI University Hospital, Oujda, Morocco
  • Hanane Saadi Department of Gynecology and Obstetrics, Mohammed VI University Hospital, Oujda, Morocco
  • Ahmed Mimouni Department of Gynecology and Obstetrics, Mohammed VI University Hospital, Oujda, Morocco

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20221299

Keywords:

Ectopic pregnancy, Methotrexate, β-hCG, Medical treatment of ectopic pregnancy

Abstract

Ectopic pregnancy occurs when the embryo implants outside the uterine cavity. It is a leading source of morbidity and mortality within pregnancy. Methotrexate, a folic acid antagonist, has been widely used to treat appropriately selected ectopic pregnancies. We report the case of a 20-year-old woman, married, G2P0, having as antecedent a right tubal ectopic pregnancy benefiting from a right salpingectomy two years ago, who presents actually a paucisymptomatic ectopic pregnancy. Medical treatment with methotrexate was chosen with monitoring of the patient's hemodynamic status and hCG level.

References

Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United States, 1991–1997. Obstet Gynecol. 2003;101:289-96.

Hajenius PJ, Engelsbel S, Mol BW, Van der Veen F, Ankum WM, Bossuyt PM, et al. Randomised trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy. Lancet. 1997;350:774-9.

Ankum WM, Mol BW, Van der Veen F, Bossuyt PM. Risk factors for ectopic pregnancy: a meta-analysis. Fertil Steril. 1996;65:1093-9.

Butts S, Sammel M, Hummel A, Chittams J, Barnhart K. Risk factors and clinical features of recurrent ectopic pregnancy: a case control study. Fertil Steril. 2003;80:1340-4.

Lipscomb GH, Stovall TG, Ling FW. Nonsurgical treatment of ectopic pregnancy. N Engl J Med. 2000;343:1325-9.

Rodi IA, Sauer MV, Gorrill MJ, Bustillo M, Gunning JE, Marshall JR et al. The medical treatment of unruptured ectopic pregnancy with methotrexate and citrovorum rescue: preliminary experience. Fertil Steril. 1986;46:811-3.

Calabresi P, Chabner BA. Antineoplastic agents. In: Gilman A, Goodman LS, Goodman A, eds. The pharmacologic basis of therapeutics. ed 8. New York: Macmillan Publishing. 1990:1275-6.

Barnhart K, Coutifaris C, Esposito M. The pharmacology of methotrexate. Expert Opin Pharmacother. 2001;2:409-17.

Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unruptured ectopic pregnancy. Fertil Steril. 1989;51:435-8.

Ory SJ, Villanueva AL, Sand PK, Tamura RK. Conservative treatment of ectopic pregnancy with methotrexate. Am J Obstet Gynecol. 1986;1546:1299-306.

Pisarska MD, Carson SA, Buster JE. Ectopic pregnancy. Lancet. 1998;351:1115-20.

Fernandez H, Lelaidier C, Thouvenez V, Frydman R. The use of a pretherapeutic, predictive score to determine inclusion criteria for the non-surgical treatment of ectopic pregnancy. Hum Reprod. 1991;6:995-8.

Fernandez H, Pauthier S, Doumerc S, Lelaidier C, Olivennes F, Ville Y, et al. Ultrasound-guided injection of methotrexate versus laparoscopic salpingotomy in ectopic pregnancy. Fertil Steril. 1995;63:25-9.

Downloads

Published

2022-04-27

Issue

Vol. 11 No. 5 (2022): May 2022

Section

Case Reports